Track the Apnimed, Inc. share price and the full management transaction log of the company, a publicly traded company based in United States. Shares are listed on the US market, under the oversight of SEC (Form 4). Market capitalisation: €1.2bn. The latest transaction was filed on 5 August 2026 (C). Among the most active insiders: Miller Lawrence G.. All data is free.
25
Insider Decl.
n/a
Thresholds
€5m
2 ops.
Buy Volume
n/a
6 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Apnimed, Inc. Strong Buy (bullish), based on 2 analysts. Average price target: US$50.50.
40Σ signal
Buys €5mn/a Sells
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 19,271 of 29,057 companies
41.1
score / 100
Value
26
Quality
56
FCF yld-6.6%
Earn yld-0.1%
EV/EBITDA·
ROE·
Gross mgn83%
Net mgn-2.4%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
Apnimed, Inc. is a company listed on the XNAS market, focused on developing treatments for sleep disorders. It emphasizes innovation in health and therapeutic solutions.